Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 5/20 | 0.66 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.42 |
| ▸ | SCD | O00767 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | GRM7 | Q14831 | 3/20 | 0.39 |
| ▸ | ABL1 | P00519 | 2/20 | 0.38 |
| ▸ | F10 | P00742 | 4/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1811240 | 0.91 | LPAR1 (0.64) | LPAR1FFAR4SCDPDE4DGRM7 | |
| SCHEMBL1811246 | 0.91 | LPAR1 (0.64) | LPAR1FFAR4SCDPDE4DGRM7 | |
| SCHEMBL1811242 | 0.91 | LPAR1 (0.64) | LPAR1FFAR4SCDPDE4DGRM7 | |
| SCHEMBL1560966 | 0.88 | LPAR1 (0.61) | LPAR1FFAR4SCDPDE4DGRM7 | |
| SCHEMBL13464534 | 0.88 | LPAR1 (0.85) | LPAR1F10 | |
| SCHEMBL1811932 | 0.80 | LPAR1 (0.84) | LPAR1PDE4DF10 | |
| SCHEMBL1810284 | 0.80 | LPAR1 (1.00) | LPAR1F10 | |
| SCHEMBL1812645 | 0.80 | LPAR1 (0.84) | LPAR1PDE4DF10 | |
| SCHEMBL1811345 | 0.80 | LPAR1 (0.51) | LPAR1FFAR4ABL1 | |
| SCHEMBL1811347 | 0.80 | LPAR1 (0.51) | LPAR1FFAR4ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120264790-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264790-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | LPAR2, LIPG, EDF1 | LPAR1 4/4885FFAR4 108/4885SCD 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.